Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 289

1.

Proteome-wide analysis of CD8+ T cell responses to EBV reveals differences between primary and persistent infection.

Forrest C, Hislop AD, Rickinson AB, Zuo J.

PLoS Pathog. 2018 Sep 24;14(9):e1007110. doi: 10.1371/journal.ppat.1007110. eCollection 2018 Sep.

2.

Epstein-Barr virus-associated lymphomas.

Shannon-Lowe C, Rickinson AB, Bell AI.

Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732). pii: 20160271. doi: 10.1098/rstb.2016.0271. Review.

3.

Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases.

Abbott RJ, Pachnio A, Pedroza-Pacheco I, Leese AM, Begum J, Long HM, Croom-Carter D, Stacey A, Moss PAH, Hislop AD, Borrow P, Rickinson AB, Bell AI.

J Virol. 2017 Oct 13;91(21). pii: e00382-17. doi: 10.1128/JVI.00382-17. Print 2017 Nov 1.

4.

Transient reduction in IgA+ and IgG+ memory B cell numbers in young EBV-seropositive children: the Generation R Study.

van den Heuvel D, Jansen MA, Bell AI, Rickinson AB, Jaddoe VW, van Dongen JJ, Moll HA, van Zelm MC.

J Leukoc Biol. 2017 Apr;101(4):949-956. doi: 10.1189/jlb.5VMAB0616-283R. Epub 2016 Nov 7.

PMID:
27821468
5.

Compartmentalization of Total and Virus-Specific Tissue-Resident Memory CD8+ T Cells in Human Lymphoid Organs.

Woon HG, Braun A, Li J, Smith C, Edwards J, Sierro F, Feng CG, Khanna R, Elliot M, Bell A, Hislop AD, Tangye SG, Rickinson AB, Gebhardt T, Britton WJ, Palendira U.

PLoS Pathog. 2016 Aug 19;12(8):e1005799. doi: 10.1371/journal.ppat.1005799. eCollection 2016 Aug.

6.

Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination.

Brooks JM, Long HM, Tierney RJ, Shannon-Lowe C, Leese AM, Fitzpatrick M, Taylor GS, Rickinson AB.

PLoS Pathog. 2016 Apr 20;12(4):e1005549. doi: 10.1371/journal.ppat.1005549. eCollection 2016 Apr.

7.

Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event.

Burns DM, Tierney R, Shannon-Lowe C, Croudace J, Inman C, Abbotts B, Nagra S, Fox CP, Chaganti S, Craddock CF, Moss P, Rickinson AB, Rowe M, Bell AI.

Blood. 2015 Dec 17;126(25):2665-75. doi: 10.1182/blood-2015-08-665000. Epub 2015 Oct 8.

8.

Primary immunodeficiencies and the control of Epstein-Barr virus infection.

Palendira U, Rickinson AB.

Ann N Y Acad Sci. 2015 Nov;1356:22-44. doi: 10.1111/nyas.12937. Epub 2015 Sep 28. Review.

PMID:
26415106
9.

Early virological and immunological events in asymptomatic Epstein-Barr virus infection in African children.

Jayasooriya S, de Silva TI, Njie-jobe J, Sanyang C, Leese AM, Bell AI, McAulay KA, Yanchun P, Long HM, Dong T, Whittle HC, Rickinson AB, Rowland-Jones SL, Hislop AD, Flanagan KL.

PLoS Pathog. 2015 Mar 27;11(3):e1004746. doi: 10.1371/journal.ppat.1004746. eCollection 2015 Mar.

10.

Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection.

Palser AL, Grayson NE, White RE, Corton C, Correia S, Ba Abdullah MM, Watson SJ, Cotten M, Arrand JR, Murray PG, Allday MJ, Rickinson AB, Young LS, Farrell PJ, Kellam P.

J Virol. 2015 May;89(10):5222-37. doi: 10.1128/JVI.03614-14. Epub 2015 Mar 18.

11.

The immunology of Epstein-Barr virus-induced disease.

Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD.

Annu Rev Immunol. 2015;33:787-821. doi: 10.1146/annurev-immunol-032414-112326. Epub 2015 Feb 11. Review.

PMID:
25706097
12.

The Epstein-Barr virus BamHI C promoter is not essential for B cell immortalization in vitro, but it greatly enhances B cell growth transformation.

Tierney RJ, Nagra J, Rowe M, Bell AI, Rickinson AB.

J Virol. 2015 Mar;89(5):2483-93. doi: 10.1128/JVI.03300-14. Epub 2014 Dec 24.

13.

A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.

Taylor GS, Jia H, Harrington K, Lee LW, Turner J, Ladell K, Price DA, Tanday M, Matthews J, Roberts C, Edwards C, McGuigan L, Hartley A, Wilson S, Hui EP, Chan AT, Rickinson AB, Steven NM.

Clin Cancer Res. 2014 Oct 1;20(19):5009-22. doi: 10.1158/1078-0432.CCR-14-1122-T. Epub 2014 Aug 14.

14.

A mutation in X-linked inhibitor of apoptosis (G466X) leads to memory inflation of Epstein-Barr virus-specific T cells.

Lopez-Granados E, Stacey M, Kienzler AK, Sierro S, Willberg CB, Fox CP, Rigaud S, Long HM, Hislop AD, Rickinson AB, Patel S, Latour S, Klenerman P, Chapel H.

Clin Exp Immunol. 2014 Dec;178(3):470-82. doi: 10.1111/cei.12427.

15.

Emerging topics in human tumor virology.

Masucci MG, Rickinson AB.

Semin Cancer Biol. 2014 Jun;26:1-3. doi: 10.1016/j.semcancer.2014.04.006. Epub 2014 Apr 23. No abstract available.

PMID:
24769056
16.

Co-infections, inflammation and oncogenesis: future directions for EBV research.

Rickinson AB.

Semin Cancer Biol. 2014 Jun;26:99-115. doi: 10.1016/j.semcancer.2014.04.004. Epub 2014 Apr 18. Review.

PMID:
24751797
17.

Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory.

Rickinson AB, Long HM, Palendira U, Münz C, Hislop AD.

Trends Immunol. 2014 Apr;35(4):159-69. doi: 10.1016/j.it.2014.01.003. Epub 2014 Mar 1. Review.

18.

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53.

Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T, Valente LJ, Robati M, Tai L, Fairlie WD, Lee EF, Lindstrom MS, Wiman KG, Huang DC, Bouillet P, Rowe M, Rickinson AB, Herold MJ, Strasser A.

Genes Dev. 2014 Jan 1;28(1):58-70. doi: 10.1101/gad.232009.113.

19.

CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response.

Abbott RJ, Quinn LL, Leese AM, Scholes HM, Pachnio A, Rickinson AB.

J Immunol. 2013 Dec 1;191(11):5398-409. doi: 10.4049/jimmunol.1301629. Epub 2013 Oct 21.

20.

MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response.

Long HM, Chagoury OL, Leese AM, Ryan GB, James E, Morton LT, Abbott RJ, Sabbah S, Kwok W, Rickinson AB.

J Exp Med. 2013 May 6;210(5):933-49. doi: 10.1084/jem.20121437. Epub 2013 Apr 8.

21.

Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients.

Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, Stocken DD, Rickinson AB, Steven NM, Chan AT.

Cancer Res. 2013 Mar 15;73(6):1676-88. doi: 10.1158/0008-5472.CAN-12-2448. Epub 2013 Jan 24.

22.

Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature.

Kelly GL, Stylianou J, Rasaiyaah J, Wei W, Thomas W, Croom-Carter D, Kohler C, Spang R, Woodman C, Kellam P, Rickinson AB, Bell AI.

J Virol. 2013 Mar;87(5):2882-94. doi: 10.1128/JVI.03003-12. Epub 2012 Dec 26.

23.

Epstein-Barr virus and infectious mononucleosis: what students can teach us.

Rickinson AB, Fox CP.

J Infect Dis. 2013 Jan 1;207(1):6-8. doi: 10.1093/infdis/jis647. Epub 2012 Oct 24. No abstract available.

PMID:
23100564
24.

The Seville expert workshop for progress in posttransplant lymphoproliferative disorders.

Glotz D, Chapman JR, Dharnidharka VR, Hanto DW, Castro MC, Hirsch HH, Leblond V, Mehta AK, Moulin B, Pagliuca A, Pascual J, Rickinson AB, Russo FP, Trappe RU, Webster AC, Zuckermann AO, Gross TG.

Transplantation. 2012 Oct 27;94(8):784-93. doi: 10.1097/TP.0b013e318269e64f.

PMID:
22992767
25.

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM.

Nature. 2012 Oct 4;490(7418):116-20. doi: 10.1038/nature11378. Epub 2012 Aug 12.

26.

Epstein-Barr virus infection of naïve B cells in vitro frequently selects clones with mutated immunoglobulin genotypes: implications for virus biology.

Heath E, Begue-Pastor N, Chaganti S, Croom-Carter D, Shannon-Lowe C, Kube D, Feederle R, Delecluse HJ, Rickinson AB, Bell AI.

PLoS Pathog. 2012;8(5):e1002697. doi: 10.1371/journal.ppat.1002697. Epub 2012 May 10.

27.

Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus.

Palendira U, Low C, Bell AI, Ma CS, Abbott RJ, Phan TG, Riminton DS, Choo S, Smart JM, Lougaris V, Giliani S, Buckley RH, Grimbacher B, Alvaro F, Klion AD, Nichols KE, Adelstein S, Rickinson AB, Tangye SG.

J Exp Med. 2012 May 7;209(5):913-24. doi: 10.1084/jem.20112391. Epub 2012 Apr 9.

28.

Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction.

Simpson AA, Mohammed F, Salim M, Tranter A, Rickinson AB, Stauss HJ, Moss PA, Steven NM, Willcox BE.

Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21176-81. doi: 10.1073/pnas.1108422109. Epub 2011 Dec 12.

29.

Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP.

Palendira U, Low C, Chan A, Hislop AD, Ho E, Phan TG, Deenick E, Cook MC, Riminton DS, Choo S, Loh R, Alvaro F, Booth C, Gaspar HB, Moretta A, Khanna R, Rickinson AB, Tangye SG.

PLoS Biol. 2011 Nov;9(11):e1001187. doi: 10.1371/journal.pbio.1001187. Epub 2011 Nov 1.

31.

The role of tetraspanin CD63 in antigen presentation via MHC class II.

Petersen SH, Odintsova E, Haigh TA, Rickinson AB, Taylor GS, Berditchevski F.

Eur J Immunol. 2011 Sep;41(9):2556-61. doi: 10.1002/eji.201141438. Epub 2011 Aug 4.

32.

Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition.

Long HM, Leese AM, Chagoury OL, Connerty SR, Quarcoopome J, Quinn LL, Shannon-Lowe C, Rickinson AB.

J Immunol. 2011 Jul 1;187(1):92-101. doi: 10.4049/jimmunol.1100590. Epub 2011 May 27.

33.

EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP.

Horst D, Favaloro V, Vilardi F, van Leeuwen HC, Garstka MA, Hislop AD, Rabu C, Kremmer E, Rickinson AB, High S, Dobberstein B, Ressing ME, Wiertz EJ.

J Immunol. 2011 Mar 15;186(6):3594-605. doi: 10.4049/jimmunol.1002656. Epub 2011 Feb 4.

34.

Immune defence against EBV and EBV-associated disease.

Long HM, Taylor GS, Rickinson AB.

Curr Opin Immunol. 2011 Apr;23(2):258-64. doi: 10.1016/j.coi.2010.12.014. Epub 2011 Jan 25. Review.

PMID:
21269819
35.

Epstein-Barr virus latent gene sequences as geographical markers of viral origin: unique EBNA3 gene signatures identify Japanese viruses as distinct members of the Asian virus family.

Sawada A, Croom-Carter D, Kondo O, Yasui M, Koyama-Sato M, Inoue M, Kawa K, Rickinson AB, Tierney RJ.

J Gen Virol. 2011 May;92(Pt 5):1032-43. doi: 10.1099/vir.0.030023-0. Epub 2011 Jan 19.

PMID:
21248177
36.

A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.

Fox CP, Haigh TA, Taylor GS, Long HM, Lee SP, Shannon-Lowe C, O'Connor S, Bollard CM, Iqbal J, Chan WC, Rickinson AB, Bell AI, Rowe M.

Blood. 2010 Nov 11;116(19):3695-704. doi: 10.1182/blood-2010-06-292268. Epub 2010 Jul 29.

37.

Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets.

Hislop AD, Palendira U, Leese AM, Arkwright PD, Rohrlich PS, Tangye SG, Gaspar HB, Lankester AC, Moretta A, Rickinson AB.

Blood. 2010 Oct 28;116(17):3249-57. doi: 10.1182/blood-2009-09-238832. Epub 2010 Jul 19.

38.

Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display.

Leung CS, Haigh TA, Mackay LK, Rickinson AB, Taylor GS.

Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2165-70. doi: 10.1073/pnas.0909448107. Epub 2010 Jan 19.

39.

EBV meets its match.

Fox CP, Rickinson AB.

Blood. 2010 Feb 4;115(5):920-1. doi: 10.1182/blood-2009-11-252437. No abstract available.

40.

T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display.

Mackay LK, Long HM, Brooks JM, Taylor GS, Leung CS, Chen A, Wang F, Rickinson AB.

PLoS Pathog. 2009 Dec;5(12):e1000699. doi: 10.1371/journal.ppat.1000699. Epub 2009 Dec 18.

41.

Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology.

Rowe M, Kelly GL, Bell AI, Rickinson AB.

Semin Cancer Biol. 2009 Dec;19(6):377-88. doi: 10.1016/j.semcancer.2009.07.004. Epub 2009 Jul 18. Review.

42.

Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infection.

Sauce D, Larsen M, Abbott RJ, Hislop AD, Leese AM, Khan N, Papagno L, Freeman GJ, Rickinson AB.

J Virol. 2009 Sep;83(18):9068-78. doi: 10.1128/JVI.00141-09. Epub 2009 Jul 15.

43.

Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.

Croft NP, Shannon-Lowe C, Bell AI, Horst D, Kremmer E, Ressing ME, Wiertz EJ, Middeldorp JM, Rowe M, Rickinson AB, Hislop AD.

PLoS Pathog. 2009 Jun;5(6):e1000490. doi: 10.1371/journal.ppat.1000490. Epub 2009 Jun 26.

44.

CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells.

Long HM, Zuo J, Leese AM, Gudgeon NH, Jia H, Taylor GS, Rickinson AB.

Blood. 2009 Jul 23;114(4):807-15. doi: 10.1182/blood-2008-12-194043. Epub 2009 May 14.

45.

Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification.

Shannon-Lowe C, Adland E, Bell AI, Delecluse HJ, Rickinson AB, Rowe M.

J Virol. 2009 Aug;83(15):7749-60. doi: 10.1128/JVI.00108-09. Epub 2009 May 13.

46.

Epstein-Barr virus colonization of tonsillar and peripheral blood B-cell subsets in primary infection and persistence.

Chaganti S, Heath EM, Bergler W, Kuo M, Buettner M, Niedobitek G, Rickinson AB, Bell AI.

Blood. 2009 Jun 18;113(25):6372-81. doi: 10.1182/blood-2008-08-175828. Epub 2009 Apr 7.

47.

An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link.

Kelly GL, Long HM, Stylianou J, Thomas WA, Leese A, Bell AI, Bornkamm GW, Mautner J, Rickinson AB, Rowe M.

PLoS Pathog. 2009 Mar;5(3):e1000341. doi: 10.1371/journal.ppat.1000341. Epub 2009 Mar 13.

48.

Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.

Horst D, van Leeuwen D, Croft NP, Garstka MA, Hislop AD, Kremmer E, Rickinson AB, Wiertz EJ, Ressing ME.

J Immunol. 2009 Feb 15;182(4):2313-24. doi: 10.4049/jimmunol.0803218.

49.

Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition.

Brooks JM, Lee SP, Leese AM, Thomas WA, Rowe M, Rickinson AB.

J Immunol. 2009 Feb 15;182(4):1919-28. doi: 10.4049/jimmunol.0713607.

50.

The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children.

Njie R, Bell AI, Jia H, Croom-Carter D, Chaganti S, Hislop AD, Whittle H, Rickinson AB.

J Infect Dis. 2009 Jan 1;199(1):31-8. doi: 10.1086/594373.

PMID:
19032105

Supplemental Content

Loading ...
Support Center